JP2002534379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002534379A5 JP2002534379A5 JP2000591989A JP2000591989A JP2002534379A5 JP 2002534379 A5 JP2002534379 A5 JP 2002534379A5 JP 2000591989 A JP2000591989 A JP 2000591989A JP 2000591989 A JP2000591989 A JP 2000591989A JP 2002534379 A5 JP2002534379 A5 JP 2002534379A5
- Authority
- JP
- Japan
- Prior art keywords
- anion
- bretylium
- pharmaceutically acceptable
- acceptable salts
- embedded image
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001450 anions Chemical class 0.000 description 79
- AAQOQKQBGPPFNS-UHFFFAOYSA-N bretylium Chemical compound CC[N+](C)(C)CC1=CC=CC=C1Br AAQOQKQBGPPFNS-UHFFFAOYSA-N 0.000 description 60
- 239000003814 drug Substances 0.000 description 36
- 230000001737 promoting effect Effects 0.000 description 27
- 229960002624 bretylium tosilate Drugs 0.000 description 25
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 21
- -1 tosylate anion Chemical class 0.000 description 21
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 description 12
- 239000002220 antihypertensive agent Substances 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- 229940030600 antihypertensive agent Drugs 0.000 description 9
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 8
- 229940043264 dodecyl sulfate Drugs 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 8
- 229960001860 salicylate Drugs 0.000 description 8
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 7
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229940068372 acetyl salicylate Drugs 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- SSILHZFTFWOUJR-UHFFFAOYSA-N hexadecane-1-sulfonic acid Chemical compound CCCCCCCCCCCCCCCCS(O)(=O)=O SSILHZFTFWOUJR-UHFFFAOYSA-N 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 5
- 239000002876 beta blocker Substances 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 101100379079 Emericella variicolor andA gene Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000003440 anti-fibrillation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11514399P | 1999-01-08 | 1999-01-08 | |
| US60/115,143 | 1999-01-08 | ||
| US11656799P | 1999-01-21 | 1999-01-21 | |
| US60/116,567 | 1999-01-21 | ||
| PCT/US2000/000350 WO2000040232A2 (en) | 1999-01-08 | 2000-01-06 | Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002534379A JP2002534379A (ja) | 2002-10-15 |
| JP2002534379A5 true JP2002534379A5 (enExample) | 2010-06-03 |
| JP4750278B2 JP4750278B2 (ja) | 2011-08-17 |
Family
ID=26812887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000591989A Expired - Fee Related JP4750278B2 (ja) | 1999-01-08 | 2000-01-06 | 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6482811B1 (enExample) |
| EP (1) | EP1140054B1 (enExample) |
| JP (1) | JP4750278B2 (enExample) |
| AT (1) | ATE290857T1 (enExample) |
| AU (1) | AU781996B2 (enExample) |
| CA (1) | CA2358459C (enExample) |
| DE (1) | DE60018704T2 (enExample) |
| IL (2) | IL144199A0 (enExample) |
| MX (1) | MXPA01007024A (enExample) |
| WO (1) | WO2000040232A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884792B2 (en) * | 1999-01-08 | 2005-04-26 | Marvin B. Bacaner | Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions |
| US20040019096A1 (en) * | 2001-10-23 | 2004-01-29 | Vlassios Andronis | Novel formulations of carvedilol |
| BRPI0613670A2 (pt) * | 2005-07-22 | 2011-01-25 | Procter & Gamble | composições para redução da incidência de arritmia induzida por fármacos |
| JP4750499B2 (ja) * | 2005-08-01 | 2011-08-17 | 日華化学株式会社 | イオン性液体並びにそれを用いた抗菌剤及び抗菌性繊維 |
| WO2014124208A1 (en) * | 2013-02-07 | 2014-08-14 | The Research Foundation Of The City University Of New York | NSAIDs DERIVATIVES AND USES THEREOF |
| ES2989922T3 (es) | 2015-09-17 | 2024-11-28 | Ohio State Innovation Foundation | Compuestos de carborano y métodos de uso de los mismos |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| WO2021183764A1 (en) * | 2020-03-11 | 2021-09-16 | Ohio State Innovation Foundation | Methods of modulating t-cell activation using carboranes and carborane analogs |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3038004A (en) | 1958-04-18 | 1962-06-05 | Burroughs Wellcome Co | Quaternary ammonium compounds |
| US3441649A (en) | 1966-08-18 | 1969-04-29 | Univ Minnesota | Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate |
| US3911125A (en) * | 1973-05-23 | 1975-10-07 | Marvin B Bacaner | Method of treating angina pectoris, coronary insufficiency, and preventing myocardial infarction |
| US4147768A (en) | 1976-09-13 | 1979-04-03 | Interx Research Corporation | Enteric coated digoxin and therapeutic use thereof |
| US5288498A (en) | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| ATE109659T1 (de) | 1986-03-21 | 1994-08-15 | Eurasiam Lab | Arzneimittelzusammensetzungen. |
| US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| US5036106A (en) * | 1989-09-05 | 1991-07-30 | Bacaner Marvin B | Methods for the treatment of disorders of the cardiac vascular system |
| US5914132A (en) | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JP3355593B2 (ja) | 1994-08-19 | 2002-12-09 | 信越化学工業株式会社 | 固形腸溶製剤の製造方法 |
| US5733575A (en) | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
| JP3149122B2 (ja) | 1994-11-07 | 2001-03-26 | 信越化学工業株式会社 | 固形腸溶製剤のコーティング用基剤 |
| US5686106A (en) | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
| US5980951A (en) | 1996-04-10 | 1999-11-09 | Merck & Co., Inc. | Oral coated active drugs |
-
2000
- 2000-01-06 CA CA2358459A patent/CA2358459C/en not_active Expired - Fee Related
- 2000-01-06 DE DE60018704T patent/DE60018704T2/de not_active Expired - Lifetime
- 2000-01-06 WO PCT/US2000/000350 patent/WO2000040232A2/en not_active Ceased
- 2000-01-06 AU AU26023/00A patent/AU781996B2/en not_active Ceased
- 2000-01-06 AT AT00904237T patent/ATE290857T1/de not_active IP Right Cessation
- 2000-01-06 US US09/869,940 patent/US6482811B1/en not_active Expired - Lifetime
- 2000-01-06 EP EP00904237A patent/EP1140054B1/en not_active Expired - Lifetime
- 2000-01-06 JP JP2000591989A patent/JP4750278B2/ja not_active Expired - Fee Related
- 2000-01-06 IL IL14419900A patent/IL144199A0/xx active IP Right Grant
- 2000-01-06 MX MXPA01007024A patent/MXPA01007024A/es not_active IP Right Cessation
-
2001
- 2001-07-08 IL IL144199A patent/IL144199A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3015131T3 (en) | Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof | |
| RU2193880C2 (ru) | Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта | |
| ES2547226T5 (es) | Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera | |
| JP2937376B2 (ja) | 徐放性医薬組成物 | |
| AU2004269903B2 (en) | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | |
| RU2521228C2 (ru) | Применение 5-аминолевулиновой кислоты и ее производных в твердой форме для фотодинамического лечения и диагностики | |
| US7029701B2 (en) | Composition for the treatment and prevention of ischemic events | |
| JPH0710773B2 (ja) | 一定の放出性及び即時放出性を有する薬物粒子 | |
| JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
| KR870009718A (ko) | 경구용 산에 불안정한물질의 약제 | |
| ES2247320T3 (es) | Medicamento a base de tramadol. | |
| JP6778680B2 (ja) | 錠剤 | |
| JP2004511521A (ja) | 回腸胆汁輸送の阻害化合物とＨＭＧ−ＣｏＡレダクターゼ阻害剤を含んでなる経口製剤 | |
| JP2005255687A (ja) | リゼドロネート遅延放出組成物 | |
| ES2364538T3 (es) | Combinación farmacéutica de alisquireno y valsartán. | |
| BR112015026418B1 (pt) | Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina | |
| JP2008069159A5 (enExample) | ||
| JP2002534379A5 (enExample) | ||
| JPH09503782A (ja) | ピコサルフェート剤形 | |
| US12364704B2 (en) | Fospropofol salts, methods and compositions | |
| CA2606740A1 (en) | Quinine-containing controlled-release formulations | |
| JP2004505034A (ja) | 制御された放出のシグモイドパターンを示すエレトリプタンの粒状組成物 | |
| US20180008558A1 (en) | Extended release compositions of an aminoalkyl nitrate | |
| JPH0710745A (ja) | 放出開始時間制御型腸デリバリー経口製剤 | |
| BRPI0615014A2 (pt) | composição farmacêutica sólida compreendendo 1-(4-cloroanilino)-4-(4-piridilmetil)ftalazina e um modificador de ph e uso da mesma |